50+ major pharma companies invest in Treg cell-based autoimmune disease therapies, with 55 treatments in clinical stages.
Treg cell-based therapies, which target the immune system to treat autoimmune diseases, are gaining traction, with over 50 major pharmaceutical companies involved. More than 55 therapies are in various clinical stages. Noteworthy developments include partnerships and Fast Track designations for specific therapies. The pipeline report offers insights into the therapeutic landscape, highlighting opportunities and challenges within this expanding field.
October 28, 2024
3 Articles